RE:RE:Intercept Pharma takeover chatter sends stock soaringI made a post on MYL's deal which paid over 13x EBITDA. That's more than 100% premium over the stock price at the time of the deal, more than 2015 and all time high I believe. Deal market right now decouples from the stock market. Control premium is very expensive these days.
The reality is that no pharma company could raise drug prices any more after the VRX fiasco. Volume is a tough game reflected this week in Teva results.So the only growth option left is M&A. Even with tightening credit market, pharma companies are cash machines that are always looking for places to deploy cash.